Sensitive detection of off-target effects is important for translating CRISPR-Cas9 nucleases into human therapeutics. In vitro biochemical methods for finding off-targets offer potential advantages of greater reproducibility and scalability while avoiding limitations associated with strategies that require the culture and manipulation of living cells. Here we describe CIRCLE-seq (Circularization for In vitro
Reporting of CLeavage Effects by sequencing), a highly sensitive, sequencing-efficient in vitro screening strategy that outperforms existing cell-based or biochemical approaches for identifying CRISPR-Cas9 genome-wide off-target mutations. In contrast to previously described in vitro methods, we show that CIRCLE-seq can be practiced using widely accessible next-generation sequencing technology and does not require reference genome sequence. Importantly, CIRCLE-seq can be used to identify off-target mutations associated with cell-type-specific SNPs, demonstrating the feasibility and importance of generating personalized specificity profiles. CIRCLE-seq provides the most accessible, rapid and comprehensive method for identifying genome-wide off-target mutations of CRISPR-Cas9 described to date.
Broad use of CRISPR-Cas12a (formerly Cpf1) nucleases
1
has been hindered by the requirement for
an extended TTTV protospacer adjacent motif (PAM)
2
. To address this limitation, we
engineered an enhanced
Acidaminococcus sp.
Cas12a variant
(enAsCas12a) that has a substantially expanded targeting range, enabling
targeting of many previously inaccessible PAMs. On average, enAsCas12a exhibits
two-fold higher genome editing activity on sites with canonical TTTV PAMs
compared to wild-type AsCas12a, and we successfully grafted a subset of
mutations from enAsCas12a onto other previously described AsCas12a
variants
3
to enhance
their activities. enAsCas12a improves the efficiency of multiplex gene editing,
endogenous gene activation, and C-to-T base editing, and we engineered a
high-fidelity version of enAsCas12a (enAsCas12a-HF1) to reduce off-target
effects. Both enAsCas12a and enAsCas12a-HF1 function in HEK293T and primary
human T cells when delivered as ribonucleoprotein (RNP) complexes. Collectively,
enAsCas12a provides an optimized version of Cas12a that should enable wider
application of Cas12a enzymes for gene and epigenetic editing. [AU: Revised
abstract OK?]
Highlights d Cancer-associated fibroblasts contribute to pancreatic cancer heterogeneity d Cancer cells can have a double-positive phenotype: proliferation and invasion d High CAF abundance linked with DP cells enriched for MAPK and STAT3 co-signaling d Intra-tumoral gland types provide tissue heterogeneity linked with clinical outcome
CRISPR-Cas genome-editing nucleases hold substantial promise for developing human therapeutic applications but identifying unwanted off-target mutations is important for clinical translation. A well-validated method that can reliably identify off-targets in vivo has not been described to date, which means it is currently unclear whether and how frequently these mutations occur. Here we describe 'verification of in vivo off-targets' (VIVO), a highly sensitive strategy that can robustly identify the genome-wide off-target effects of CRISPR-Cas nucleases in vivo. We use VIVO and a guide RNA deliberately designed to be promiscuous to show that CRISPR-Cas nucleases can induce substantial off-target mutations in mouse livers in vivo. More importantly, we also use VIVO to show that appropriately designed guide RNAs can direct efficient in vivo editing in mouse livers with no detectable off-target mutations. VIVO provides a general strategy for defining and quantifying the off-target effects of gene-editing nucleases in whole organisms, thereby providing a blueprint to foster the development of therapeutic strategies that use in vivo gene editing.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.